Skip to main content
. 2023 Oct 21;22:284. doi: 10.1186/s12933-023-02011-2

Table 1.

Baseline characteristics of patients stratified by the TyG index tertiles

Variable T1 (n = 210) T2 (n = 211) T3 (n = 212) P value
Age, years 70.28 ± 10.53 67.50 ± 10.46 66.31 ± 10.91 < 0.001
Female, n (%) 67 (31.9) 71 (33.6) 70 (33.0) 0.928
BMI, kg/m2 24.24 ± 2.93 24.99 ± 2.85 25.45 ± 3.40 < 0.001
Smoking, n (%) 90 (42.9) 95 (45.0) 99 (46.7) 0.729
Previous PCI, n (%) 28 (13.3) 16 (7.6) 24 (11.3) 0.154
COPD, n (%) 11 (5.2) 8 (3.8) 9 (4.2) 0.762
Hypertension, n (%) 156 (74.3) 165 (78.2) 156 (73.6) 0.495
AF, n (%) 19 (9.0) 13 (6.2) 20 (9.4) 0.408
Previous stroke, n (%) 15 (7.1) 8 (3.8) 13 (6.1) 0.313
SBP, mmHg 133.19 ± 21.80 134.00 ± 22.87 134.79 ± 21.21 0.459
HR, bpm 77.51 ± 13.86 77.36 ± 14.72 81.45 ± 15.72 0.006
cTnT, pg/mL 25.90 (13.80, 550.40) 28.66 (13.00, 502.10) 49.17 (14.00, 459.30) 0.388
BNP, pg/mL 97.90 (40.55, 304.25) 99.60 (34.70, 328.80) 137.18 (45.93, 485.15) 0.132
Scr, µmol/L 79.85 (66.70, 98.35) 76.00 (64.00, 92.70) 78.55 (63.03, 101.20) 0.248
Uric acid, µmol/L 369.76 ± 117.54 386.24 ± 125.92 379.99 ± 127.59 0.387
FBG, mmol/L 6.70 ± 2.06 8.38 ± 2.49 10.28 ± 3.85 < 0.001
HbA1c 7.00 ± 1.40 7.74 ± 1.78 8.04 ± 1.78 < 0.001
TG, mmol/L 1.01 ± 0.29 1.38 ± 0.39 2.22 ± 0.99 < 0.001
TC, mmol/L 3.98 ± 1.13 4.40 ± 1.28 4.78 ± 1.27 < 0.001
HDL-C, mmol/L 1.17 ± 0.30 1.09 ± 0.28 1.12 ± 0.30 0.012
LDL-C, mmol/L 2.37 ± 0.78 2.68 ± 0.89 2.93 ± 0.90 < 0.001
LVEF 55.01 ± 9.39 55.43 ± 9.37 53.28 ± 10.23 0.053
AMI, n (%) 89 (42.4) 89 (42.2) 106 (50.0) 0.183
Diagnosis, n (%) 0.429
 CCS 33 (15.7) 35 (16.6) 22 (10.4)
 UA 88 (41.9) 87 (41.2) 84 (39.6)
 NSTEMI 48 (22.9) 43 (20.4) 53 (25.0)
 STEMI 41 (19.5) 46 (21.8) 53 (25.0)
Aspirin, n (%) 204 (97.1) 206 (97.6) 203 (95.3) 0.519
P2Y12 receptor inhibitor, n (%) 208 (99.0) 210 (99.5) 208 (98.1) 0.368
Statins, n (%) 203 (96.7) 206 (97.6) 209 (98.6) 0.432
β-Blockers, n (%) 145 (69.0) 145 (68.7) 162 (76.4) 0.141
ACEI/ARB, n (%) 100 (47.6) 108 (51.2) 112 (52.8) 0.550
Diuretics, n (%) 39 (18.6) 47 (22.3) 53 (25.0) 0.278
Insulin, n (%) 45 (21.4) 62 (29.4) 60 (28.3) 0.133
Oral hypoglycemic agents, n (%) 145 (69.0) 156 (73.9) 149 (70.3) 0.516
MVD, n (%) 151 (71.9) 154 (73.0) 168 (79.2) 0.172
LM, n (%) 11 (5.2) 24 (11.4) 10 (4.7) 0.013
Calcified lesions, n (%) 38 (18.1) 39 (18.5) 42 (19.8) 0.894
Thrombosis, n (%) 19 (9.0) 16 (7.6) 23 (10.8) 0.507
Long lesion, n (%) 125 (59.9) 130 (61.6) 141 (66.5) 0.314
CTO, n (%) 41 (19.5) 39 (18.5) 59 (27.8) 0.039
Number of stents 1.51 ± 0.92 1.51 ± 0.94 1.58 ± 0.96 0.643
Length of stents, mm 39.18 ± 26.43 40.05 ± 28.58 43.20 ± 29.07 0.301
TyG index 8.50 ± 0.32 9.05 ± 0.13 9.67 ± 0.38 < 0.001
bSS 14.00 (8.00, 21.00) 16.00 (9.00, 21.50) 15.75 (10.00, 21.38) 0.379
rSS 3.00 (0.00, 8.00) 5.00 (0.00, 9.00) 4.00 (1.00, 9.00) 0.286

Data are presented as mean ± SD, median (IQR) or n (%)

BMI body mass index, PCI percutaneous coronary intervention, COPD chronic obstructive pulmonary disease, AF atrial fibrillation, SBP systolic blood pressure, HR heart rate, BNP brain natriuretic peptide, Scr serum creatinine, FBG fasting blood glucose, TG triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, LVEF left ventricular ejection fraction, AMI acute myocardial infarction, CCS chronic coronary syndrome, UA unstable angina, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction, ACEI/ARB angiotensin converting enzyme inhibitor/angiotensin receptor blocker, MVD multivessel disease, LM left main disease, CTO chronic total occlusion, TyG index the triglyceride-glucose index, bSS baseline SYNTAX score, rSS residual SYNTAX score, T1 TyG index < 8.85, T2 8.85 ≤ TyG index < 9.28, T3 TyG index ≥ 9.28